Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | MAT2A | P31153 | 3/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 3/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5949580 | 0.78 | CYP1A2 (0.47) | MAPTHPGDCYP2C19MEN1CYP1A2 | |
| SCHEMBL9215901 | 0.74 | MAPT (0.44) | MAPTHPGDCYP2C19MEN1CYP1A2 | |
| SCHEMBL7281964 | 0.73 | HPGD (0.53) | MAPTHPGDCYP2C19MEN1CYP1A2 | |
| SCHEMBL5249954 | 0.73 | HPGD (0.64) | MAPTHPGDCYP2C19MEN1CYP1A2 | |
| SCHEMBL10427752 | 0.70 | KMT2A (0.50) | MAPTHPGDCYP2C19MEN1CYP1A2 | |
| SCHEMBL9131244 | 0.70 | MAPT (0.50) | MAPTHPGDCYP2C19MEN1CYP1A2 | |
| SCHEMBL9535601 | 0.70 | MAPT (0.50) | MAPTHPGDCYP2C19MEN1CYP1A2 | |
| SCHEMBL9267553 | 0.70 | MAPT (0.47) | MAPTHPGDCYP2C19MEN1CYP1A2 | |
| SCHEMBL6009928 | 0.69 | MAPT (0.49) | MAPTHPGDCYP2C19MEN1CYP1A2 | |
| SCHEMBL9132147 | 0.69 | MAPT (0.52) | MAPTHPGDCYP2C19MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613318-A4 | COMPOUNDS AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORP (US) | 2009-03-11 | — | — | EP | claimed |
| US-20060094714-A1 | Compounds and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-05-04 | — | — | US | claimed |
| EP-1613318-A2 | COMPOUNDS AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2006-01-11 | — | — | EP | claimed |
| WO-2004087880-A2 | COMPOUNDS AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-10-14 | — | — | WO | claimed |
| EP-1613318-A4 | COMPOUNDS AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORP (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20060094714-A1 | Compounds and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-05-04 | — | — | US | disclosed |
| EP-1613318-A2 | COMPOUNDS AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087880-A2 | COMPOUNDS AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094714-A1 | Compounds and their use to treat diabetes and related disorders | IAPP, SLC5A2, SLC5A1 | MAPT 1563/4885HPGD 771/4885CYP2C19 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.